Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial.

Abstract

BACKGROUND AND AIMS:

Pharmacy administration and dispensing of methadone for methadone maintenance treatment (MMT) can expand treatment access for opioid use disorder (OUD). This study investigated the feasibility and acceptability of a novel model permitting an opioid treatment program (OTP) physician to prescribe methadone for OUD treatment through collaboration with a partnered pharmacy.

DESIGN:

Non-randomized, single-arm, open-label feasibility trial.

SETTING:

One OTP and one community pharmacy in the United States.

PARTICIPANTS:

One OTP physician, two pharmacists and 20 MMT patients receiving between six and 13 take-home methadone doses at 5-160 mg/day.

INTERVENTION:

Patients' methadone administration and dispensing of take-home doses was transferred from the OTP to the pharmacy for 3 months.

MEASUREMENTS:

Primary outcome was medication adherence. Secondary outcomes were recruitment, treatment retention, substance use, counseling attendance at the OTP, pharmacist prescription drug monitoring program (PDMP) use, safety and satisfaction.

FINDINGS:

Of 29 patients eligible at pre-screen, 20 patients (69%) enrolled into the study. Recruitment occurred from 6 August 2020 to 10 October 2020. Treatment retention rate at month 3 was 80% (16 of 20). Two participants returned early to the OTP because of a work/schedule change, one due to pregnancy and one following a non-study-related hospitalization. Medication adherence among 16 patients who were retained was 100%. Intervention fidelity was 100%. All participants attended random call-back visits. None showed evidence of tampering/diversion of methadone. Pharmacists checked the PDMP at all visits. All participants attended psychosocial counseling as planned. There were no positive urine screens for illicit opioid use and no study-related adverse events. All participants endorsed 'pharmacy is the right location for receiving methadone for MMT', 88% endorsed 'convenient or very convenient to receive methadone at the pharmacy' and 88% were satisfied or very satisfied with the quality of treatment offered.

CONCLUSIONS:

This feasibility trial has found pharmacy administration and dispensing of physician-prescribed methadone for methadone maintenance treatment to be feasible and acceptable.

• Authors: Li-Tzy Wu, William S John, Eric D Morse, Steve Adkins, Jennifer Pippin, Robert K Brooner, Robert P Schwartz
• Journal: Addiction (Abingdon, England) (Addiction) Vol. 117 Issue 2 Pg. 444-456 (02 2022) ISSN: 1360-0443 [Electronic] England
• PMID: 34286886 (Publication Type: Clinical Trial, Journal Article, Research Support, N.I.H., Extramural)
• Copyright: © 2021 Society for the Study of Addiction.

Chemical References

• Analgesics, Opioid
• Methadone

Topics

• Analgesics, Opioid (therapeutic use)
• Feasibility Studies
• Humans
• Methadone (therapeutic use)
• Opiate Substitution Treatment
• Opioid-Related Disorders (drug therapy)
• Pharmacies
• Pharmacy